A detailed history of Graham Capital Management, L.P. transactions in Exelixis, Inc. stock. As of the latest transaction made, Graham Capital Management, L.P. holds 10,938 shares of EXEL stock, worth $364,126. This represents 0.01% of its overall portfolio holdings.

Number of Shares
10,938
Holding current value
$364,126
% of portfolio
0.01%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$21.96 - $27.6 $240,198 - $301,888
10,938 New
10,938 $283,000
Q2 2023

Aug 14, 2023

BUY
$18.17 - $20.48 $249,383 - $281,088
13,725 New
13,725 $262,000
Q3 2022

Nov 14, 2022

SELL
$15.68 - $22.27 $123,166 - $174,930
-7,855 Reduced 29.44%
18,828 $295,000
Q2 2022

Aug 15, 2022

BUY
$17.44 - $23.16 $258,827 - $343,717
14,841 Added 125.33%
26,683 $555,000
Q1 2022

May 16, 2022

SELL
$17.03 - $22.67 $238 - $317
-14 Reduced 0.12%
11,842 $268,000
Q4 2021

Feb 14, 2022

BUY
$15.84 - $21.88 $187,799 - $259,409
11,856 New
11,856 $216,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $10.7B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Graham Capital Management, L.P. Portfolio

Follow Graham Capital Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Graham Capital Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Graham Capital Management, L.P. with notifications on news.